Wall Street Zen upgraded shares of Polyrizon (NASDAQ:PLRZ – Free Report) to a sell rating in a research note published on Saturday.
Polyrizon Stock Performance
PLRZ opened at $0.77 on Friday. The stock has a 50 day moving average price of $75.48. Polyrizon has a 1-year low of $0.55 and a 1-year high of $1,200.00.
Hedge Funds Weigh In On Polyrizon
An institutional investor recently bought a new position in Polyrizon stock. Citadel Advisors LLC acquired a new stake in shares of Polyrizon Ltd. (NASDAQ:PLRZ – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 38,337 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned approximately 0.91% of Polyrizon at the end of the most recent quarter.
About Polyrizon
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.
Featured Stories
- Five stocks we like better than Polyrizon
- What Investors Need to Know About Upcoming IPOs
- Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead
- Manufacturing Stocks Investing
- Top 3 ETFs Defense Hawks Are Buying
- Roth IRA Calculator: Calculate Your Potential Returns
- Zscaler Will Hit $360 Soon: Here’s the How and Why
Receive News & Ratings for Polyrizon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polyrizon and related companies with MarketBeat.com's FREE daily email newsletter.
